Volume 144, Issue 2, Pages (February 2013)

Slides:



Advertisements
Similar presentations
Oxidized Low-Density Lipoprotein Is a Novel Predictor of Interferon Responsiveness in Chronic Hepatitis C Infection  Philipp Solbach, Sandra Westhaus,
Advertisements

Volume 132, Issue 3, Pages (March 2007)
Molecular Therapy - Methods & Clinical Development
Volume 138, Issue 5, Pages e10 (May 2010)
Volume 122, Issue 5, Pages (May 2002)
Volume 135, Issue 5, Pages e1 (November 2008)
Volume 143, Issue 4, Pages e4 (October 2012)
Volume 143, Issue 2, Pages e8 (August 2012)
Les Lang  Gastroenterology  Volume 133, Issue 1, (July 2007)
Volume 132, Issue 2, Pages (February 2007)
Volume 137, Issue 4, Pages (October 2009)
Volume 154, Issue 4, Pages e6 (March 2018)
Volume 141, Issue 4, Pages e6 (October 2011)
Les Lang  Gastroenterology  Volume 133, Issue 1, (July 2007)
Volume 141, Issue 3, Pages e4 (September 2011)
Volume 134, Issue 5, Pages e1 (May 2008)
Volume 135, Issue 6, Pages (December 2008)
Volume 140, Issue 2, Pages e1 (February 2011)
Volume 132, Issue 2, Pages (February 2007)
Volume 137, Issue 3, Pages e7 (September 2009)
Volume 143, Issue 4, Pages e9 (October 2012)
Lost in Inflammation: The Functional Conversion of Regulatory T Cells in Acute Hepatitis A Virus Infection  Tobias Boettler, Robert Thimme  Gastroenterology 
Volume 134, Issue 5, Pages (May 2008)
Volume 138, Issue 5, Pages e2 (May 2010)
Volume 150, Issue 1, Pages e4 (January 2016)
HLA-A*0201+ Plasmacytoid Dendritic Cells Provide a Cell-Based Immunotherapy for Melanoma Patients  Caroline Aspord, Marie-Therese Leccia, Dimitri Salameire,
Volume 128, Issue 2, Pages (February 2005)
Volume 145, Issue 5, Pages (November 2013)
Volume 134, Issue 1, Pages (January 2008)
Volume 133, Issue 4, Pages (October 2007)
Effects and Regulation of Autoreactive CD8+ T Cells in a Transgenic Mouse Model of Autoimmune Hepatitis  Mario Zierden, Elisabeth Kühnen, Margarete Odenthal,
Volume 143, Issue 3, Pages (September 2012)
Volume 138, Issue 4, Pages (April 2010)
Volume 141, Issue 3, Pages (September 2011)
Volume 143, Issue 6, Pages e4 (December 2012)
Volume 154, Issue 4, Pages (March 2018)
Volume 138, Issue 3, Pages (March 2010)
Volume 155, Issue 5, Pages e2 (November 2018)
Volume 136, Issue 4, Pages (April 2009)
Volume 153, Issue 5, Pages e2 (November 2017)
Volume 143, Issue 2, Pages e8 (August 2012)
Volume 154, Issue 6, Pages (May 2018)
Volume 134, Issue 7, Pages e2 (June 2008)
Volume 132, Issue 3, Pages (March 2007)
Volume 135, Issue 5, Pages e2 (November 2008)
Volume 140, Issue 1, Pages e3 (January 2011)
Volume 132, Issue 2, Pages (February 2007)
Volume 135, Issue 6, Pages (December 2008)
Volume 31, Issue 1, Pages (July 2009)
Volume 134, Issue 7, Pages e3 (June 2008)
Volume 138, Issue 2, Pages e4 (February 2010)
Covering the Cover Gastroenterology
HLA-A*0201+ Plasmacytoid Dendritic Cells Provide a Cell-Based Immunotherapy for Melanoma Patients  Caroline Aspord, Marie-Therese Leccia, Dimitri Salameire,
Volume 143, Issue 1, Pages e3 (July 2012)
Volume 127, Issue 3, Pages (September 2004)
Volume 135, Issue 1, Pages (July 2008)
Volume 134, Issue 7, Pages e2 (June 2008)
Volume 117, Issue 6, Pages (December 1999)
A comparison of gene transfer and antigen-loaded dendritic cells for the generation of CD4+ and CD8+ cytomegalovirus-specific T cells in HLA-A2+ and HLA-A2−
Volume 137, Issue 4, Pages e6 (October 2009)
Volume 137, Issue 2, Pages (August 2009)
Volume 138, Issue 1, Pages (January 2010)
Sulfatide-Mediated Activation of Type II Natural Killer T Cells Prevents Hepatic Ischemic Reperfusion Injury In Mice  Philomena Arrenberg, Igor Maricic,
Volume 147, Issue 4, Pages e8 (October 2014)
Volume 132, Issue 1, Pages 5-6 (January 2007)
Immune Quiescence and Hepatitis B Virus: Tolerance Has Its Limits
Volume 135, Issue 3, Pages (September 2008)
Volume 131, Issue 6, Pages (December 2006)
Volume 142, Issue 7, Pages e6 (June 2012)
Volume 138, Issue 2, Pages e4 (February 2010)
Presentation transcript:

Volume 144, Issue 2, Pages 426-436 (February 2013) Factors That Determine the Antiviral Efficacy of HCV-Specific CD8+ T Cells Ex Vivo  Bianca Seigel, Bertram Bengsch, Volker Lohmann, Ralf Bartenschlager, Hubert E. Blum, Robert Thimme  Gastroenterology  Volume 144, Issue 2, Pages 426-436 (February 2013) DOI: 10.1053/j.gastro.2012.10.047 Copyright © 2013 AGA Institute Terms and Conditions

Figure 1 Differential antiviral efficacy of virus-specific CD8+ T cells. (A) Ex vivo tetramer frequencies from all patients and representative tetramer stainings after CD8+ T-cell selection are shown. Patients with ex vivo tetramer-positive CD8+ T cells ≥0.01% were included. (B) Ex vivo antiviral efficacy of virus-specific CD8+ T cells targeting Flu-, EBV-, CMV-, or HCV-specific epitopes was analyzed. Huh7A2HCV cells were pulsed with the respective viral peptides and cocultured for 72 hours with CD8+ T cells at an E/T ratio of 2:1. Only consensus and not autologous variant peptides were used. Inhibition of replication was measured by luciferase activity. (C–E) Ex vivo antiviral efficacy of virus-specific CD8+ T cells targeting (C) HCV-, (D) EBV-, and (E) Flu-specific epitopes was analyzed. Correlation of tetramer frequencies with inhibition of replication is shown. Each dot represents one patient. cHCV, chronic hepatitis C virus. Gastroenterology 2013 144, 426-436DOI: (10.1053/j.gastro.2012.10.047) Copyright © 2013 AGA Institute Terms and Conditions

Figure 2 Antiviral efficacy is linked to IFN-γ production of virus-specific CD8+ T cells. (A) Comparison of tetramer-positive CD8+ T cells and CD8+ T cells producing IFN-γ after peptide-specific stimulation for 5 hours. (B) Huh7A2HCV cells pulsed with Flu-, EBV-, or HCV-specific viral peptides and cocultured for 72 hours with CD8+ T cells at an E/T ratio of 2:1 and additionally in the presence of 10 μg/mL anti–IFN-γ. (C and D) Representative stainings and antiviral efficacy of one patient. (C) Percent values indicate the tetramer-positive CD8+ T cells after CD8+ T-cell selection (upper panel) and IFN-γ+CD8+ T cells (lower panel), respectively. (D) Huh7A2HCV cells were pulsed with Flu-, EBV-, or HCV (NS31073)-specific viral peptides and cocultured for 72 hours with CD8+ T cells at an E/T ratio of 2:1. Inhibition of replication was measured by luciferase activity. Assay was performed in triplicate. (E and F) Tetramer-positive CD8+ T cells were fluorescence-activated cell sorted and cocultured with 30,000 Huh7A2HCV cells pulsed with Flu-, EBV-, or HCV-specific viral peptides for 72 hours at different E/T ratios. Cell numbers of tetramer-positive CD8+ T cells are indicated. cHCV, chronic hepatitis C virus. Gastroenterology 2013 144, 426-436DOI: (10.1053/j.gastro.2012.10.047) Copyright © 2013 AGA Institute Terms and Conditions

Figure 3 Antiviral efficacy correlates with expression levels of CD127. (A) Two groups of HCV-specific CD8+ T cells can be distinguished by level of CD127 expression. High levels of CD127 expression (>80%) are displayed by black boxes and low expression by black circles. (B) Two representative stains for low CD127 and high CD127 expression levels (gated on CD8+ T cells). (C) Expression of PD-1 and 2B4 is shown for CD127− and CD127+ HCV-specific CD8+ T cells (***P = .0006; *P = .027). (D) Frequencies are shown for CD127− and CD127+ HCV-specific T cells. (E) Inhibition of replication of CD127− and CD127+ HCV-specific CD8+ T cells was measured by luciferase activity (P = .0451). Gastroenterology 2013 144, 426-436DOI: (10.1053/j.gastro.2012.10.047) Copyright © 2013 AGA Institute Terms and Conditions

Figure 4 Antiviral efficacy is inversely correlated to expression levels of PD-1. (A and B) Huh7A2HCV cells were pulsed with HCV-specific viral peptides and cocultured for 72 hours with CD8+ T cells at an E/T ratio of 2:1. Correlation of (A) PD-1 and (B) 2B4 expression and inhibition of replication is shown. Representative tetramer staining for low and high (A) PD-1 and (B) 2B4 expression is shown. Stainings are gated on CD8+ T cells. Gastroenterology 2013 144, 426-436DOI: (10.1053/j.gastro.2012.10.047) Copyright © 2013 AGA Institute Terms and Conditions

Figure 5 Differential cytokine responsiveness of CD127− and CD127+ HCV-specific CD8+ T cells. (A) Huh7A2HCV cells labeled with HCV (NS31406)-specific viral peptide and cocultured for 72 hours with CD8+ T cells of one representative patient at an E/T ratio of 2:1 in the presence of cytokines. (Left panel) Unlabeled Huh7A2HCV cells. Dashed lines indicate the baseline effect of adding CD8+ T cells to Huh7A2HCV cells. Assays were performed independently at 3 different time points. ***P <.001. (B) Huh7A2HCV cells were labeled with viral peptides and cocultured for 72 hours with CD8+ T cells at an E/T ratio of 2:1 in the presence of cytokines or blocking reagents. Open boxes indicate CD127+PD-1− and black boxes indicate CD127−PD-1+ HCV-specific CD8+ T cells. Inhibition of replication was measured by luciferase activity. An increase in inhibition of replication compared with baseline is depicted. A total of 7 chronically infected patients were analyzed. Tetramer-specific responses with >50% PD-1 expression were categorized as PD-1+. Gastroenterology 2013 144, 426-436DOI: (10.1053/j.gastro.2012.10.047) Copyright © 2013 AGA Institute Terms and Conditions

Figure 6 Differential antiviral efficacy of HCV-specific CD8+ T cells of patients with SVR and patients with SpR. (A) Ex vivo antiviral efficacy of virus-specific CD8+ T cells targeting HCV-specific epitopes obtained from patients with chronic HCV infection (cHCV), SVR, and SpR were analyzed. Huh7A2HCV cells were pulsed with the HCV-specific peptides and cocultured for 72 hours with CD8+ T cells at an E/T ratio of 2:1. Inhibition of replication was measured by luciferase activity as relative luciferase units. (B) Comparison of tetramer-positive CD8+ T cells and CD8+ T cells producing IFN-γ after peptide-specific stimulation for 5 hours. (C) The coculture assay was performed additionally in the presence of 10 μg/mL anti–IFN-γ. Results for patients with SpR and patients with cHCV are shown. (D) Expression of CD127, PD-1, and 2B4 on HCV-specific CD8+ T cells of patients with SpR is shown. Gastroenterology 2013 144, 426-436DOI: (10.1053/j.gastro.2012.10.047) Copyright © 2013 AGA Institute Terms and Conditions

Supplementary Figure 1 Gastroenterology 2013 144, 426-436DOI: (10.1053/j.gastro.2012.10.047) Copyright © 2013 AGA Institute Terms and Conditions

Supplementary Figure 2 Gastroenterology 2013 144, 426-436DOI: (10.1053/j.gastro.2012.10.047) Copyright © 2013 AGA Institute Terms and Conditions